2022
Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis
Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O’Donnell MR. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases 2022, 75: 1489-1496. PMID: 35352097, PMCID: PMC9617578, DOI: 10.1093/cid/ciac232.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisHuman immunodeficiency virusMDR-TB treatmentART adherenceART resistanceHuman immunodeficiency virus/AIDSEmergent resistanceStandard of careResource-limited settingsTB regimensAntiretroviral resistanceHIV RNAProspective cohortMedication adherenceImmunodeficiency virusPoor outcomeShort followAdherence thresholdCopies/Treatment outcomesDose monitoringResistance mutationsResistance testingPublic hospitalsLinear association
2019
Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison
Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM, Emery S, Molina JM, Orkin C, Gatell J, Gerstoft J, Ruxrungtham K, de Souza M, Phillips AN. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison. AIDS 2019, 33: 2337-2350. PMID: 31764099, PMCID: PMC6882545, DOI: 10.1097/qad.0000000000002359.Peer-Reviewed Original ResearchConceptsEarly antiretroviral treatmentHIV-serodifferent partnersAntiretroviral treatmentMonth 12Month 24CD4 cell countHIV-positive adultsSexual behaviorHIV infectiousnessImmediate armViral suppressionPrimary outcomeHigh prevalenceCondomless sexCell countMSMCells/Lower absolute levelsSexHeterosexual menTreatmentHeterosexualsArmAbsolute levelsPrevalenceAntiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection
O'Donnell MR, Padayatchi N, Daftary A, Orrell C, Dooley KE, Amico K, Friedland G. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. The Lancet HIV 2019, 6: e201-e204. PMID: 30846058, PMCID: PMC7155388, DOI: 10.1016/s2352-3018(19)30035-9.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisBedaquiline treatmentTuberculosis-HIVLow antiretroviral therapy adherencePotent new therapyAntiretroviral therapy initiationAntiretroviral therapy adherenceEfavirenz-containing regimensFixed-dose combinationAntiretroviral therapy switchMiddle-income settingsDaily nevirapineAdherence supportAntiretroviral resistanceAntiretroviral therapyHIV patientsTherapy initiationViral failureTherapy switchImproved survivalTherapy adherenceDrug interactionsNew therapiesHIVBedaquiline
2015
Trends in hospital deaths among human immunodeficiency virus–infected patients during the antiretroviral therapy era, 1995 to 2011
Cowell A, Shenoi SV, Kyriakides TC, Friedland G, Barakat LA. Trends in hospital deaths among human immunodeficiency virus–infected patients during the antiretroviral therapy era, 1995 to 2011. Journal Of Hospital Medicine 2015, 10: 608-614. PMID: 26130520, PMCID: PMC4560992, DOI: 10.1002/jhm.2409.Peer-Reviewed Original ResearchConceptsHospital deathAIDS deathsHuman immunodeficiency virus-infected patientsHigher CD4 cell countsAIDS infectionAntiretroviral therapy eraNon-AIDS deathsNon-AIDS malignanciesCD4 cell countHIV viral loadVirus-infected patientsHuman immunodeficiency virusUrban teaching hospitalTimes greater likelihoodCardiovascular comorbiditiesTherapy eraCD4 countInpatient mortalityImmunodeficiency syndromeLiver diseaseUnderlying liverViral loadImmunodeficiency virusMedical recordsAntiretroviral era
2014
HIV Prevention Counseling Intervention Delivered During Routine Clinical Care Reduces HIV Risk Behavior in HIV-Infected South Africans Receiving Antiretroviral Therapy
Fisher JD, Cornman DH, Shuper PA, Christie S, Pillay S, Macdonald S, Ngcobo N, Amico KR, Lalloo U, Friedland G, Fisher WA. HIV Prevention Counseling Intervention Delivered During Routine Clinical Care Reduces HIV Risk Behavior in HIV-Infected South Africans Receiving Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2014, 67: 499-507. PMID: 25230288, PMCID: PMC4229426, DOI: 10.1097/qai.0000000000000348.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Retroviral AgentsCounselingFemaleHIV InfectionsHumansMaleMiddle AgedRisk-TakingSexual BehaviorSouth AfricaYoung AdultConceptsHIV risk behaviorsAntiretroviral therapyClinical care sitesLay counsellorsRisk behaviorsCare sitesRoutine clinical careStandard of careClinical care settingsCounseling interventionHIV careViral suppressionPrimary outcomeHIV statusRoutine careCare counselingCare participantsEffective behavioral interventionsHIV epidemicHIV preventionIntervention participantsCare settingsClinical careBrief interventionInfection incidence
2013
Case 29-2013 — A 32-Year-Old HIV-Positive African Man with Dyspnea and Skin Lesions
Cabot R, Rosenberg E, Harris N, Shepard J, Cort A, Ebeling S, McDonald E, Friedland G, Naidoo P, Abdool-Gafoor B, Moosa M, Ramdial P, Gandhi R. Case 29-2013 — A 32-Year-Old HIV-Positive African Man with Dyspnea and Skin Lesions. New England Journal Of Medicine 2013, 369: 1152-1161. PMID: 24047065, DOI: 10.1056/nejmcpc1305985.Peer-Reviewed Original ResearchThe Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment
Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, Ramanathan S, Friedland GH. The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 63: 480-484. PMID: 23599011, DOI: 10.1097/qai.0b013e3182961d31.Peer-Reviewed Original ResearchConceptsEVG/COBIBuprenorphine/naloxoneBaseline valuesBuprenorphine/naloxone treatmentEffect of elvitegravirElvitegravir/cobicistatOpioid-dependence therapiesHIV-seronegative subjectsNorbuprenorphine levelsOpioid pharmacodynamicsOpioid withdrawalNaloxone treatmentPharmacodynamic interactionsBuprenorphine/Historical controlsPharmacodynamic studiesAUCtauCobicistatNaloxoneCmaxElvitegravirTherapySubjectsCOBISteady-state evaluationA review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadone
2012
The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial.
Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N, Nair G, Bamber S, Gengiah S, El-Sadr WM, Friedland G, Abdool Karim S. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Annals Of Internal Medicine 2012, 157: 313-24. PMID: 22944873, PMCID: PMC3534856, DOI: 10.7326/0003-4819-157-5-201209040-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAntibiotics, AntitubercularAnti-Retroviral AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHumansImmune Reconstitution Inflammatory SyndromeImmunocompromised HostIncidenceKaplan-Meier EstimateMaleProspective StudiesRifampinRisk FactorsSeverity of Illness IndexTuberculosisConceptsImmune reconstitution inflammatory syndromeSequential treatment groupIncidence of IRISReconstitution inflammatory syndromeAntiretroviral therapy initiationART initiationTreatment groupsIRIS incidenceSAPiT trialInflammatory syndromeTherapy initiationTreatment initiationTuberculosis treatmentOpen-label clinical trialCells/LCo-infected patientsEarly ART initiationInitiation of ARTTuberculosis treatment initiationSmear-negative tuberculosisHigher hospitalization ratesWeeks of completionBaseline CD4Antituberculosis treatmentNonambulatory patientsRisk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting
Gandhi N, Andrews J, Brust J, Montreuil R, Weissman D, Heo M, Moll A, Friedland G, Shah N. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 90-97. PMID: 22236852, PMCID: PMC3302205, DOI: 10.5588/ijtld.11.0153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountCoinfectionDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisFemaleHIV InfectionsHumansMaleMarkov ChainsMonte Carlo MethodPrevalencePrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSouth AfricaSurvival AnalysisTime FactorsTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryConceptsHuman immunodeficiency virusXDR-TB patientsRisk factorsAntiretroviral therapyXDR-TBDrug-resistant (XDR) TBImmunosuppressed human immunodeficiency virusStrong independent risk factorHigh HIV prevalence settingsMDR-TB patientsTB treatment programsIndependent risk factorYear of diagnosisDrug-resistant tuberculosisHIV prevalence settingsCells/Principal risk factorsCase-control studyAmplification of resistanceHigh mortality rateART initiationHIV testingImmunodeficiency virusPrevalence settingsMortality rate
2011
Integration of Antiretroviral Therapy with Tuberculosis Treatment
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, Gengiah T, Gengiah S, Naidoo A, Jithoo N, Nair G, El-Sadr WM, Friedland G, Abdool Karim Q. Integration of Antiretroviral Therapy with Tuberculosis Treatment. New England Journal Of Medicine 2011, 365: 1492-1501. PMID: 22010915, PMCID: PMC3233684, DOI: 10.1056/nejmoa1014181.Peer-Reviewed Original ResearchConceptsImmune reconstitution inflammatory syndromeT-cell countsEarly ART groupLater-ART groupInitiation of ARTAntiretroviral therapyTuberculosis treatmentIncidence rateCubic millimeterAdverse eventsRisk of IRISHuman immunodeficiency virus (HIV) infectionReconstitution inflammatory syndromeMedian viral loadImmunodeficiency virus infectionAIDS-free survivalRisk of AIDSHigher CD4Median CD4Inflammatory syndromeAmbulatory patientsImmunodeficiency syndromeViral loadContinuation phaseAntiretroviral drugsComputer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project
Fisher JD, Amico KR, Fisher WA, Cornman DH, Shuper PA, Trayling C, Redding C, Barta W, Lemieux AF, Altice FL, Dieckhaus K, Friedland G, for the LifeWindows Team. Computer-Based Intervention in HIV Clinical Care Setting Improves Antiretroviral Adherence: The LifeWindows Project. AIDS And Behavior 2011, 15: 1635. PMID: 21452051, DOI: 10.1007/s10461-011-9926-x.Peer-Reviewed Original ResearchConceptsHIV clinical care settingsAdherence support interventionsClinical care sitesClinical care settingsHIV careCare visitsAntiretroviral adherenceControl armCare settingsCare sitesProtocol interventionTreat sampleProtocol sampleSupport interventionsComputer-based interventionsIntervention impactControl participantsInterventionAdherenceHIVPatientsCareHigh levelsClinicARVCulture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa
Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, Li X, Loveday M, Bamber SA, Lalloo UG, Friedland GH, Shah NS, Gandhi NR. Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa. PLOS ONE 2011, 6: e15841. PMID: 21253585, PMCID: PMC3017058, DOI: 10.1371/journal.pone.0015841.Peer-Reviewed Original ResearchConceptsMDR-TB patientsCulture conversion rateMDR-TB treatmentMonths of therapyAntiretroviral therapyHIV-coCulture conversionHIV co-infected patientsMultidrug-resistant tuberculosis patientsTiming of ARTMDR-TB therapyCo-infected patientsHIV-negative patientsSecond-line regimenSimilar cure ratesDays of initiationResource-limited settingsHIV prevalentART medicationsCD4 countMDR-TBTuberculosis patientsSputum cultureSuch patientsHIV status
2010
The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis
Karim Q, Karim S, Baxter C, Friedland G, Gengiah T, Gray A, Grobler A, Naidoo K, Padayatchi N, El-Sadr W. The SAPIT trial provides essential evidence on risks and benefits of integrated and sequential treatment of HIV and tuberculosis. South African Medical Journal 2010, 100: 808-809. PMID: 21414268, DOI: 10.7196/samj.4621.Peer-Reviewed Original ResearchTiming of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. New England Journal Of Medicine 2010, 362: 697-706. PMID: 20181971, PMCID: PMC3076221, DOI: 10.1056/nejmoa0905848.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHIVHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedPatient ComplianceRNA, ViralTuberculosisViral LoadYoung AdultConceptsSequential therapy groupHuman immunodeficiency virusAntiretroviral therapyRate of deathTuberculosis therapyHIV infectionDaily antiretroviral regimenIntegrated antiretroviral therapyIntegration of tuberculosisStandard tuberculosis therapyPositive sputum smearPrimary end pointSafety Monitoring CommitteeDiagnosis of tuberculosisAcid-fast bacilliTiming of initiationAntiretroviral regimenAdverse eventsHIV servicesImmunodeficiency virusAntiretroviral drugsSputum smearStudy groupPatientsCell count
2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLX
2007
Implementation Issues in Tuberculosis/HIV Program Collaboration and Integration: 3 Case Studies
Friedland G, Harries A, Coetzee D. Implementation Issues in Tuberculosis/HIV Program Collaboration and Integration: 3 Case Studies. The Journal Of Infectious Diseases 2007, 196: s114-s123. PMID: 17624820, DOI: 10.1086/518664.Peer-Reviewed Original ResearchConceptsTB/HIV service integrationHIV service integrationNeeds of patientsPublic health approachWorld Health OrganizationHIV diseaseNational TuberculosisHIV programsHIV interactionsInfection influenceHealth approachSuccessful outcomeTuberculosisDiseaseHealth OrganizationLarge national programProgram settingsSmall demonstration projectsMost settingsOutcomesImplementation of programsProgram collaborationNational programLarge populationService integration
2006
Introduction
Williams A, Friedland G. Introduction. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s1-s2. PMID: 17133190, DOI: 10.1097/01.qai.0000248350.33254.1c.Peer-Reviewed Original ResearchExtensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. The Lancet 2006, 368: 1575-1580. PMID: 17084757, DOI: 10.1016/s0140-6736(06)69573-1.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisCo-infected patientsXDR tuberculosisMDR tuberculosisHIV co-infected patientsCulture-confirmed tuberculosisRecent hospital admissionTime of diagnosisSecond-line drugsDrug susceptibility testingCause of deathDate of deathHigh mortality rateAntiretroviral therapyMedian survivalHospital admissionSputum cultureHIV-1PatientsMortality rateHigh mortalityUrgent interventionTreatment programTuberculosisSusceptibility testing